AKT抑制剂MK-2206治疗复发性铂耐药高级别浆液性卵巢癌、输卵管癌或原发性腹膜癌的简化II期研究结果（NCT 01283035）
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).
作者信息
Lee Elizabeth K, Tan-Wasielewski Zhenying, Aghajanian Carol, Coleman Robert L, Curtis Jennifer, Hirsch Michelle S, Matulonis Ursula A, Cantley Lewis C, Mills Gordon B, Doyle L Austin, Liu Joyce F
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, United States.
出版信息
Gynecol Oncol Rep. 2020 Feb 3;32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May.
Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.
铂耐药、复发性、高级别上皮性卵巢癌的治疗仍然具有挑战性。化疗对复发性疾病的治疗反应有限，生存获益不大。在这种情况下，靶向治疗可能会优于传统治疗。PI3K/AKT信号通路改变在包括卵巢癌在内的多种癌症类型中经常出现，因此抑制AKT是一种合理的靶向治疗方法。在此，我们报告了一项关于AKT抑制剂MK-2206在伴有PTEN缺失的铂耐药高级别浆液性卵巢癌、输卵管癌和原发性腹膜癌中的简化试验结果。
Zotero 插件